- |
My Account- |
United States (Change Country)JNJ 26854165 (Serdemetan) Chemical Structure
JNJ 26854165 (Serdemetan) is an orally bioavailable, small-molecule HDM2 antagonist with potential antineoplastic activity. JNJ 26854165 (Serdemetan) inhibits the binding of the HDM2–p53 complex to the proteasome, blocking the degradation of p53; p53 signaling and p53-mediated induction of tumor cell apoptosis may thus be restored. In addition to p53, degradation of other HDM2 client proteins may be inhibited. HDM2 (human homolog of double minute 2), a zinc finger protein, is a negative regulator of the p53 pathway; often overexpressed in cancer cells, this oncoprotein has been implicated in cancer cell proliferation and survival. [1][2]
[1] ASCO Annual Meeting 2008;Vol 26, No 15S
[2] http://www.cancer.gov/drugdictionary/?CdrID=596734 ;
| Molecular Weight (WM): | 328.41 |
|---|---|
| Formula: | C21H20N4 |
| Solubility(R.T.:25°C): | DMSO 66mg/mL |
| Water <1mg/mL | |
| Ethanol 2mg/mL |
A collection of 715 inhibitors
A collection of 271 kinase inhibitors
A collection of 785 FDA approved drugs
A collection of 144 natural products
A collection of 84 chemotherapeutic agents
A collection of 1463 bioactive compounds
A collection of 117 tyrosine kinase inhibitors
Keywords:buy JNJ 26854165 (Serdemetan) | JNJ 26854165 (Serdemetan) supplier | purchase JNJ 26854165 (Serdemetan) | JNJ 26854165 (Serdemetan) cost | JNJ 26854165 (Serdemetan) manufacturer | order JNJ 26854165 (Serdemetan) | JNJ 26854165 (Serdemetan) distributor
